Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Conditions
Myelofibrosis (PMF) · Post Essential Thrombocythemia Myelofibrosis (ET-MF) · Post Polycythemia Vera Related Myelofibrosis (PV-MF)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Moffitt Cancer Center, Tampa, Florida, United States
Contact: Principal Investigator (Andrew Kuykendall, MD)Emory University, Atlanta, Georgia, United States
Contact: Principal Investigator (Anthony Hunter, MD)Roswell Park Cancer Institute, Buffalo, New York, United States
Contact: Principal Investigator (Eunice Wang, MD)Ruttenberg Treatment Center, New York, New York, United States
Contact: Principal Investigator (Marina Kremyanskaya)Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Principal Investigator (Brian Chernak, MD)NewYork-Presbyterian/Weill Cornell Medical Center, New York, New York, United States
Contact: Principal Investigator (Ghaith Abu-Zeinah, MD)Wake Forest Baptist Health Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Contact: Principal Investigator (Rupali Bhave, MD)The Cleveland Clinic Foundation, Cleveland, Ohio, United States
Contact: Principal Investigator (Aaron Gerds, MD)The Ohio State University, Columbus, Ohio, United States
Contact: Principal Investigator (Shivani Handa, MD)
Study leads
Marina Kremyanskaya, PhD, MD
Study Chair
Icahn School of Medicine at Mount Sinai
Aaron Gerds, MD, MS
Study Chair
Cleveland Clinic Taussig Cancer Institute